New patent application – on serum TK1 levels for prediction of cancer relapse

AroCell AB announced today that a patent application has been filed in the US relating to the measurement of thymidine kinase 1 (TK1), and in particular to the prediction of cancer relapse based on measured serum TK1 levels.

The patent application is based on a study in patients with diffuse large B-cell lymphoma (DLBCL). The study showed that the TK1 concentrations in these patients could predict cancer relapse.
“This patent application broadens our area of use of TK1 in oncology. We are happy to be able to continue to develop our portfolio and expand the usability of AroCell TK 210 ELISA in oncology” says Anders Hultman, CEO AroCell.